9月30日，康方生物盘中下跌3.86%，报102.4港元，成交额1.3亿港元。
消息面上，康方生物前一交易日因阿斯利康20亿美元战略入股其海外合作伙伴Summit Therapeutics大涨15.54%，收报106.3港元，单日市值增逾130亿港元。该交易核心标的为康方生物研发的依沃西单抗——全球首个PD-1/VEGF双特异性抗体。今日股价回落，市场人士指出，短期获利盘回吐压力较大，同时投资者仍关注依沃西美国BLA审批进展等悬而未决的核心风险。此外，南向资金前一交易日对康方生物有所减持，亦反映部分资金选择在高位兑现收益。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.